If you have looked for something to take the edge off anxiety, you have almost certainly seen GABA on a supplement label. The pitch is simple: GABA is the brain’s main calming chemical, so topping it up should calm you down.
The short answer is that oral GABA probably reaches your brain in only trace amounts, and the researchers who reviewed the human evidence declined to draw a conclusion either way. The modified versions of the molecule that do reach the brain are not supplements at all, and the same chemistry that lets them work is what makes them hard to stop taking.
What GABA Actually Does in the Brain
GABA, or gamma-aminobutyric acid, is the main inhibitory neurotransmitter in the central nervous system. Where other signalling chemicals tell neurons to fire, GABA tells them to quieten down. It is the system benzodiazepines act on, and it is tied to how the brain regulates arousal and sleep onset. That is a real mechanism, and it is why the supplement idea sounds plausible. The problem is getting GABA inside the brain..
The Blood-Brain Barrier Problem
The blood-brain barrier is a tightly packed layer of cells lining the brain’s blood vessels. It lets glucose and oxygen through and blocks most else. GABA is small but highly water-soluble, precisely the profile the barrier is built to exclude.
The popular claim that GABA simply cannot cross is overstated, and so is the industry counter-claim that it can. A 2015 review in Frontiers in Psychology by Boonstra and colleagues found studies pointing both ways, complicated by a transporter that, in mice, pumps GABA out of the brain roughly 17 times faster than it lets it in. Their conclusion was blunt for a review paper: it is not possible at this time to reach a definite conclusion about GABA’s permeability in humans. A 2024 review in Nutraceuticals agreed, suggesting any effects people notice are more plausibly explained through the gut and the vagus nerve.
The direct human evidence is small. Boonstra’s team found four placebo-controlled studies of oral GABA. One showed increased alpha-wave activity on EEG, a pattern associated with relaxed wakefulness. But an EEG shift is not a reduction in anxiety, and four small studies is not a body of evidence.
Why Chemists Modified the Molecule
Soviet researchers hit this problem in the 1960s and solved it the way medicinal chemists do: they changed the molecule. Adding a phenyl ring to the beta carbon of GABA makes it far more fat-soluble, and fat-soluble molecules cross. The result was phenibut, or beta-phenyl-GABA.
It worked, in the narrow sense that the compound reaches the brain. Binding studies show it acts on two targets at once: the GABA-B receptor, and the alpha2-delta subunit of voltage-gated calcium channels, the site gabapentin binds. At both it is a weak ligand, with roughly 30 times lower affinity for GABA-B than baclofen and several hundred times lower for alpha2-delta than gabapentin. Weak binding means large quantities are needed to produce an effect, which turns out to matter.
Phenibut is a licensed prescription medicine in Russia, Latvia, Estonia and a few neighbouring countries. It holds no EU-wide marketing authorisation and is not licensed in the UK or the United States. Outside those markets it is supplied as a laboratory reference material, which is why suppliers such as Nordic Chems list research-grade phenibut HCl with a certificate of analysis and a research-use-only designation rather than as a consumer product. That distinction reflects what the evidence supports.
What the Clinical Record Shows
The World Health Organization reviewed phenibut in 2021 and stated plainly that randomised controlled trials for any of its purported indications are not available. The human efficacy literature is open-label Soviet-era trials that WHO noted are unavailable in English and contain no statistical analysis.
The harm literature is considerably better documented. Tolerance is reported within one to two weeks of regular use, in some accounts within 5 days. A 2023 systematic review in the Journal of Addiction Medicine pooled 62 published cases of toxicity and withdrawal. Among toxicity presentations, 48.7% required intubation, with an average hospital stay of five days. Among withdrawal cases, 95.7% had been daily users, 69.6% needed more than one medication to manage the syndrome, and the average stay was 7.7 days. A 2024 review in Cureus found hallucinations and insomnia each in 53% of 15 withdrawal cases.
US poison centres logged 1,320 phenibut exposures between 2009 and 2019 across all 50 states, 12.6% of major severity, with three deaths. In 86.8% of published cases, people had bought it online.
What the Label Does Not Tell You
There is a separate problem with consumer products. A 2022 analysis in Clinical Toxicology tested four phenibut-containing supplements and found one delivering more than 1,100 mg per serving, over four times the 250 mg tablet strength commonly licensed in the countries where phenibut is a medicine, with no dosage information on the label. Retested after FDA enforcement action, three of the four contained more phenibut than before.
Regulators have taken a consistent line. The MHRA seized phenibut in 2014 as an unlicensed medicinal product. Australia lists it in Schedule 9, prohibited. The FDA has ruled it does not meet the statutory definition of a dietary ingredient and treats it as an unsafe food additive.
What Has Better Evidence for Anxiety
The comparison is uncomfortable: a compound with no randomised controlled trials against interventions that have dozens.
NICE guideline CG113 sets out a stepped approach to generalised anxiety disorder: guided self-help first, with cognitive behavioural therapy or applied relaxation as the higher-intensity options if that is not enough. CBT has been assessed in repeated meta-analyses across anxiety presentations. In England you can self-refer to NHS Talking Therapies without going through your GP if you are 18 or over, or 16 or over in some areas. Other talking therapies suit people who want something less structured.
The unglamorous things also help: consistent sleep and wake times, regular physical activity, less alcohol and caffeine. If you prefer a natural approach, some herbal options for anxiety and stress have a longer safety record than novel GABA analogues, though efficacy evidence varies case by case.
When to See a GP
Anxiety that responds to lifestyle changes is one thing. Anxiety that does not is worth a conversation.
See your GP promptly if:
- Anxiety has interfered with work, relationships or sleep for more than a few weeks
- You are using alcohol or any substance to manage symptoms
- You have unchecked physical symptoms such as chest pain or breathlessness
- You have been taking any GABA-active compound regularly and want to stop
That last point matters. Stopping abruptly after regular use of a GABA-B active compound can produce a withdrawal syndrome that includes agitation, hallucinations and seizures. It is managed medically, usually with a supervised taper. Do not attempt it alone.
Call 999 or go to A&E if you experience seizures, severe confusion, or hallucinations.
The Bottom Line
Oral GABA supplements are unlikely to do much, and the reviewers who looked hardest say the human evidence is not good enough to settle it either way.
The compounds that solved the blood-brain barrier problem solved it too well. Phenibut reaches the brain, and the published record on what follows is dominated by tolerance, dependence and hospital admissions rather than evidence of benefit. There is a reason it is supplied to laboratories with a certificate of analysis rather than sold as a wellness product.
If anxiety is the actual problem, the interventions with real evidence behind them are also the ones you can access this month.
Frequently Asked Questions
Is GABA safe to take as a supplement?
Oral GABA is generally well tolerated at supplement doses and no serious safety signal has emerged. The open question is whether it does anything, not whether it causes harm. Tell your GP about any supplement you take regularly, particularly alongside prescribed medication.
Is phenibut legal in the UK?
It is not a controlled drug under the Misuse of Drugs Act, but it falls within the scope of the Psychoactive Substances Act 2016, which makes supply and importation an offence, and it is not a licensed medicine here. Possessing it for personal use is not itself an offence, though possession with intent to supply is, as is possession in a custodial institution. It is legally supplied in the UK only as a laboratory research chemical.
Why is phenibut sold as a research chemical rather than a supplement?
Regulators in the UK, US and Australia have not approved it for human use, and the evidence does not support approval. There are no randomised controlled trials for any indication, while the dependence and withdrawal literature is substantial. Supplying it as documented research material with a certificate of analysis reflects that position.
Useful Sources
- NHS: Anxiety, fear and panic – nhs.uk/mental-health/feelings-symptoms-behaviours/feelings-and-symptoms/anxiety-fear-panic/
- NICE Guideline CG113: Generalised anxiety disorder and panic disorder in adults – nice.org.uk/guidance/cg113
- Boonstra E et al. (2015). Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Frontiers in Psychology – frontiersin.org
- Weleff J et al. (2023). Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review. Journal of Addiction Medicine – pubmed.ncbi.nlm.nih.gov/36745903
- Graves JM et al. (2020). Notes from the Field: Phenibut Exposures Reported to Poison Centers, United States, 2009-2019. MMWR – cdc.gov/mmwr/volumes/69/wr/mm6935a5.htm
- WHO Expert Committee on Drug Dependence (2021). Phenibut Pre-Review Report – ecddrepository.org/en/phenibut
DISCLAIMER: The Site cannot and does not contain medical / health advice. The medical / health information is provided for general informational and educational purposes only and is not a substitute for professional advice. Accordingly, before seeking any form of medical advice, diagnoses or treatment based upon such information, we encourage you to consult with your GP or other qualified health practitioner. You must never disregard professional medical advice or delay in seeking it because of something mentioned on this Site. The use or reliance of any information contained on the Site is solely at your own risk.
